Development of a French version of the Endometriosis Health Profile 5 (EHP-5): cross-cultural adaptation and psychometric evaluation

Huchon, Cyrille; Chaillou, Laura; Aubry, Gabrielle; Renouvel, F.; Panel, P.

doi:10.1007/s11136-016-1346-y

Cited by 14 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most commonly used scales are accurately validated (SF-36, SF-12, EHP-30, EHP-5, EQ5D, NHP, WHOQOL-BREF, DUKE HEALTH PROFILE, 15D) and reliable. Information on other psychometric properties, such as reproducibility (often obtained with the test-retest phase) or responsiveness (the ability to detect a response to treatment or a change in health status, which is of major importance) is in some cases provided (SF-36 [60], EHP-5 [61], [62] EHP-30 [4,38,63] E5-QD [61].…”

Section: Resultsmentioning

confidence: 99%

“…Information on construct validity and responsiveness may be incomplete as for the EHP-5 (not fully studied in the original version). However, the French version of the EHP-5 is reported as having good psychometric properties and to be an efficient, valid and responsive tool suitable for daily pratice [61,62].…”

Section: Resultsmentioning

confidence: 99%

“…The EHP-30 is the specific scale for endometriosis that has been translate in most languages [38,39,68,69]. The EHP-5 underwent cross-cultural adaption in three countries: France, Turkey and Iran [62,70,71].…”

Section: Resultsmentioning

confidence: 99%

“…The EHP-5, on the other hand derived from the EHP-30, is shorter and thus could fulfill a role in evaluation of HRQoL in everyday clinical practice. It has been demonstrated that the 5+6 questions of the EHP-5 were completely one-dimensional with very high internal consistency [62]. It allows providing a single overall QoL score to measure how endometriosis impairs daily life.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Systematic review of quality of life measures in patients with endometriosis

et al. 2019

Self Cite

View full text Add to dashboard Cite

ObjectivesEndometriosis and quality of life has been the subject of much research, however, there is little consensus on how best to evaluate quality of life in endometriosis, resulting in many and diverse scales being used. In our study, we aim to identify quality of life scales used in endometriosis, to review their strengths and weaknesses and to establish what would define an ideal scale in the evaluation of endometriosis-related quality of life.Materials and methodsA search of the MEDLINE and EMBASE databases was carried out for publications in English and French for the period from 1980 to February 2017, using the words ‘endometriosis’ and ‘quality of life’. Publications were selected if they reported on quality of life in patients with endometriosis and specified use of a quality of life scale. A quantitative and a qualitative analysis of each scale was performed in order to establish the strengths and weaknesses for each scale (systematic registration number: PROSPERO 2014: CRD42014014210).ResultsA total of 1538 articles publications were initially identified. After exclusion of duplicates and application of inclusion criteria, 201 studies were selected for analysis. The SF-36, a generic HRQoL measure, was found to be the most frequently used scale, followed by the EHP-30, a measure specific to endometriosis. Both perform well, when compared with other scales, with scale weaknesses offset by strengths. EHP-5 and EQ-5D also showed to be of good quality. All four were the only scales to report on MCID studied in endometriosis patients.ConclusionFor clinical practice, routine evaluation of HRQOL in women with endometriosis is essential both for health-care providers and patients. Both SF-36 and EHP-30 perform better overall with regard to their strengths and weaknesses when compared to other scales.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review of quality of life measures in patients with endometriosis

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The data came from a French prospective observational database, which has the objective to study the quality of life in women with endometriosis 14 and the effect of different therapeutics.…”

Section: Methodsmentioning

confidence: 99%

Do high‐dose progestins impair sexual function in women treated for endometriosis? A prospective observational longitudinal study

Oppenheimer

Verdun

Perot

et al. 2020

Acta Obstet Gynecol Scand

Self Cite

View full text Add to dashboard Cite

Introduction High‐dose progestins are used as an effective therapy for painful symptoms of endometriosis but their impact on sexual function has been poorly studied. The study aims to assess the impact of high‐dose progestin on sexual function among women treated for endometriosis. Material and methods In this bicenter prospective observational study, women with endometriosis who received medical or surgical treatment for endometriosis and who were sexually active were included. They completed the Sexual Activity Questionnaire (SAQ, a validated tool) before (T0) and 12 months after (T1) endometriosis treatment. We classified patients into two groups according to whether they were using high‐dose progestins at T1: a high‐dose progestin group and a control group. The main outcome was sexual function measured by the SAQ score (from 0 to 30) at T1. The secondary outcomes were each individual SAQ item, the dyspareunia 100‐mm visual analog scale (VAS) and the quality of life assessed with EuroQoL Group 5D Index (EQ‐5D) at T1. We also assessed the change in dyspareunia VAS and quality of life between T0 and T1. The Ethics Committee of Ile‐de‐France (Act 2004‐806, 9 August 2004) approved the study. Results Among 214 women included, 25 (12%) were exposed to high‐dose progestins at T1. The SAQ score of women exposed to high‐dose progestins was significantly lower compared with the control group, with or without adjustment for covariates (15.5 ± 6.3 vs 18.3 ± 6.2, P = .03, adjusted effect size −0.44 [95% CI −0.86 to −0.02], P = .04). High‐dose progestin intake at T1 was associated with a lower subscore on two SAQ items: pleasure (1.8 ± 0.8 vs 2.2 ± 0.9, P = .02), and satisfaction with frequency of intercourse (1.2 ± 1.2 vs 1.8 ± 1.1, P = .02). In the overall population, dyspareunia VAS and quality of life assessed by EQ‐5D improved between T0 and T1 (45 ± 29 at T0 vs 28 ± 29 at T1, P < .001; 0.78 ± 0.14 at T0 vs 0.86 ± 0.14 at T1, P < .001, respectively). At T1, the groups did not differ significantly for dyspareunia VAS (effect size 0.36 [95% CI −0.06 to 0.78], P = .10) and quality of life (EQ‐5D, effect size 0.02 [95% CI −0.40 to 0.44], P = .91). Conclusion In this observational study, high‐dose progestins impair the sexual function of women treated for endometriosis even though they improved dyspareunia.

show abstract

The short form endometriosis health profile questionnaire (EHP-5): psychometric validity assessment of a Croatian version

Mikuš

Matak

Vujić

et al. 2022

Arch Gynecol Obstet

View full text Add to dashboard Cite

Purpose: To translate, adapt and validate the Endometriosis Health Pro le-5 (EHP-5) in Croatian population.Methods: This validation study is a part of a prospective, observational study (EHP-5 CRO) with aim of implementation of EHP-5 and to provide better insight in quality of life consideration of women with endometriosis in Croatian clinical practice. A 150 consecutive patients with surgically proven endometriosis were enrolled. The translation to Croatian followed standardized procedure. Cronbach's Alpha was calculated to calculate internal consistency reliability of EHP-5. The test-retest reliability was calculated using intraclass correlation coe cient (ICC). The t-test for independent samples was used to assess known-groups validity.Results: Both EHP-5 core and EHP-5 modular parts of the questionnaire had good internal consistency, assessed by the Cronbach's Alpha coe cient (α=0.793 and α=0.842, respectively). Obtained results indicate very good reliability for core as well as for modular part of EHP-5 questionnaire (ICC=0.896 and 0.936, respectively). The independent t-test showed that women who reported their pain with VAS scale 7 or more had signi cantly higher results (p<0.001) on EHP-5 (M=50.63) compared with women who reported their pain 6 or less (M=26.91). Furthermore, we found statistically signi cant difference between women who are infertile with women who are fertile (p<0.001), whereby infertile women had higher average result on EHP-5 (M=49.55) compared with fertile women (M=34.36). Conclusion:The Croatian version of the EHP-5 have very good psychometric characteristics and can be used as a reliable tool for assessing patients with endometriosis in everyday clinical practice.

show abstract

Development of a French version of the Endometriosis Health Profile 5 (EHP-5): cross-cultural adaptation and psychometric evaluation

Abstract: The French version of EHP-5 is valid and can be used for reporting patient-orientated outcome in future studies of French-speaking patients with endometriosis.

Cited by 14 publications

References 29 publications

Systematic review of quality of life measures in patients with endometriosis

Systematic review of quality of life measures in patients with endometriosis

Do high‐dose progestins impair sexual function in women treated for endometriosis? A prospective observational longitudinal study

The short form endometriosis health profile questionnaire (EHP-5): psychometric validity assessment of a Croatian version

Contact Info

Product

Resources

About